We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alkermes PLC | NASDAQ:ALKS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.24 | 0.98% | 24.68 | 22.00 | 26.74 | 24.80 | 24.30 | 24.55 | 1,016,741 | 05:00:03 |
From Apr 2019 to Apr 2024
Alkermes PLC said its depression drug helped patients not responding to standard treatments, news that added more than $3 billion to the company's market value in after-hours trading.
The company said that in a late-stage trial, its ALKS 5461 treatment significantly improved depression scores in patients who had an inadequate response to standard therapies. The most commonly reported adverse events associated with the treatment were nausea, dizziness and fatigue.
Alkermes said it plans to request a meeting with the U.S. Food and Drug Administration to discuss the filing strategy for the treatment, which has a fast-track designation.
Shares of Alkermes rose 47% to $64.10 in after-hours trading. At that price, the company has a market cap of $9.7 billion, up from its valuation of $6.59 billion at the end of the regular session Thursday.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 20, 2016 17:25 ET (21:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Alkermes Chart |
1 Month Alkermes Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
